시장보고서
상품코드
1345442

세계의 서맥 치료 기기 시장(2023-2030년)

Global Bradycardia Treatment Devices Market - 2023-2030

발행일: | 리서치사: DataM Intelligence | 페이지 정보: 영문 186 Pages | 배송안내 : 2일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

개요

서맥 치료 기기(Bradycardia Treatment Devices) 시장은 2022년 89억 달러에서, 2023-2030년 예측기간 동안 CAGR 5.0%로 성장하며 2030년에는 130억 7,000만 달러에 달할 것으로 예측됩니다.

세계의 서맥 치료 기기 시장은 역학에 영향을 미치는 다양한 요인들로 인해 수년 동안 큰 성장과 변모를 이루었습니다. 심박수 감소와 같은 심혈관 질환 증가, 의료기기에 대한 연구 개발 및 정부 투자는 서맥 치료 기기의 세계의 보급에 영향을 미치는 주요 요인 중 하나입니다. 2020년의 도전적인 한 해를 보낸 서맥 치료 기기 산업은 적절한 회복력과 적응력을 보여주었습니다.

특히 개발도상국의 심혈관 질환에 대한 정부 투자는 계속해서 심박 조율기 사용을 촉진하고 글로벌 서맥 치료 기기 시장을 활성화할 것입니다. 글로벌 서맥 치료 기기 업계는 서맥을 더 잘 관리하는 데 점점 더 중점을 두고 있습니다. 각 이니셔티브에는 서맥 치료를위한 제세동기와 같은 다른 장치의 사용이 포함되며 때로는 심박 조율기 역할을합니다.

부비동 서맥은 시장 점유율의 1/3 이상을 차지합니다. 마찬가지로 북미는 서맥 치료 기기 시장을 지배하며 1/3 이상의 가장 큰 시장 점유율을 차지하고 있습니다. 이 지역은 의료 분야에 대한 빠른 투자와 전 세계 서맥 치료 기기 시장에서 주요 업체로 부상하면서 가장 큰 시장 점유율을 차지하고 있습니다. 미국은 소비자뿐만 아니라 제조업체도 가장 많이 보유하고 있습니다.

역학

신제품 출시와 규제허가 증가

선진국에서는 높은 소득 수준, 투자 및 인프라 개발로 인해 의료 부문의 개선이 빠르게 이루어지고 있습니다. 여러 국가에서 서맥 치료 기기에 대한 수요가 크게 증가했으며, 이는 의료 산업의 확장을 반영합니다. 새로운 제품 출시와 이에 대한 규제 승인이 증가하는 것은 시장 성장을 이끄는 중요한 요인이 될 것입니다.

프랑스에 본사를 두고 있는 심장 박동 관리 부문의 세계적인 선구자인 MicroPort CRM사에 따르면 2023년 5월 18일 현재 시장에서 가장 긴 수명의 페이스메이커인 이식형 페이스메이커 Alizaea와 Cela 및 그 관련 제품에서 한 태블릿 프로그래머 SmartTouch XT, 페이싱 리드 Vega, 블루투스 홈 모니터 SmartView Connect가 모두 FDA 승인을 받았습니다. 이것은 환자 관리에 큰 승리이며 회사의 미국 시장에 대한 헌신을 이야기하고 있습니다. AutoMRI 모드는 MicroPort CRM이 개발한 획기적인 알고리즘으로 Alizea 및 Celea 제품의 특징입니다.

MRI 검사 중 환자의 안전과 QOL을 향상시킵니다. MRI 모드를 활성화하려면 환자는 검사 전 10일에 한 번만 심장 전문의의 진찰을 받아야 합니다. 일단 모드가 설정되면 심박 조율기는 MRI 필드에 들어갈 때 자동으로 MRI 모드로 이동하고 검사가 끝나면 기본 설정으로 돌아가 환자와 의료 종사자 모두의 효율성을 크게 향상시킵니다. 이 장비는 Vega 페이싱 리드를 이식할 때 1.5 테슬라 또는 3 테슬라 MRI 스캐너에서 사용이 승인됩니다.

장비 기술 진보 증가

서맥 치료 기기의 기술 발전이 증가함에 따라 향후 시장 성장을 주도 할 것입니다. 예를 들어, 2023년 5월 20일, 세계 최초의 듀얼 챔버 무연 심박 조율기는 애보트의 듀얼 챔버(DR) AVEIR i2i 임상시험용 기기 면제(IDE) 연구에서 최신 결과를 받아 이 심박 조율기가 안전성과 성능에 대해 미리 정해진 세 가지 주요 평가지표를 충족했음을 입증했습니다. 이 정보는 또한 AVEIR DR이 정상보다 느린 심장 박동을 가진 사람들에게 새로운 이점을 제공할 수 있음을 시사합니다.

세계 최초의 i2i(임플란트 대 임플란트) 기술을 통해 듀얼 챔버 무드리스 페이스메이커(DR은 듀얼 챔버 박동 반응의 약자)인 AVEIR DR 무드리스 페이스메이커를 개발했습니다. 이 두 장치는 서로 통신함으로써 다른 무연 맥박 조정기와 달리 심장 박동이 누락되거나 지연되는 것을 감지하고 적절한 심장 박동 속도를 조절할 수 있습니다.

장비와 관련된 빈번한 리콜

지난 몇 년동안 다양한 이유로 심장 박동기 리콜이 자주 발생했습니다. 예를 들어, Boston Scientific의 INGENIO 시리즈 페이스메이커는 심장혈관 재 동기화 요법 페이스메이커(CRT-P)로도 알려져 있으며 심박수가 낮은 환자와 중등도에서 심한 심부전 환자에게 사용됩니다.

2021년 8월 10일 Boston Scientific은 안전 모드에 들어갈 수 있는 것으로 INGENIO family의 CRT-P와 페이스메이커를 리콜했습니다. 안전 모드는 해당 장치가 고장나면 백업으로 작동합니다. 근육 수축을 감지하기 때문에 안전 모드에서는 부주의하게 페이싱이 손실 될 위험이 있습니다. 안전 모드로 들어가면 재프로그램이 불가능하므로 장치를 교체해야 합니다.

영향을 받은 제품을 사용하면 즉각적인 기기 교체 필요, 심박수 조절 기능 상실 또는 심각하거나 생명을 위협하는 부상(예: 의료진이 심장을 조절하기 위해 전기 펄스를 조절하는 임시 페이싱 필요), 심부전 악화 및 사망 등 건강에 심각한 부정적 영향을 미칠 수 있습니다. 문서화된 사례는 65건이며, 이 중 3건은 부상을 입은 환자에게 일시적인 외부 페이스 조절이 필요했습니다. 사망 사례는 보고되지 않았습니다.

장비와 관련된 합병증 또는 위험

혈전은 심장 박동기 사용자의 약 2%에서 발생합니다. 이것은 일반적으로 심박 조율기가 이식 된 측면의 팔 부위에서 발생합니다. 그 결과 팔이 확대될 수 있습니다. 그러나 일반적으로 며칠 이내에 사라집니다. 큰 문제가되는 것은 드뭅니다. 페이스메이커 감염은 페이스메이커를 착용 한 사람의 1%가 영향을받습니다. 심박 조율기를 사용하기 시작한 지 1년이내에 발생하는 경우가 많습니다. 수술로 의도하지 않고 폐가 파열될 수 있습니다. 이것은 폐에서 가슴으로 공기가 침투한다는 것을 의미합니다. 기흉이라는 단어는 이것을 의미합니다.

기흉이 되는 사람은 전체의 1%에 불과합니다. 일반적으로 공기 누출은 매우 적습니다. 자연스럽게 좋아지므로 치료가 필요하지 않습니다. 심박 조율기는 다른 전자 장치와 마찬가지로 매우 작은 확률로 고장납니다. 이것은 심장 박동기 오류로 알려져 있습니다. 심박 조율기는 리드선이 밀려나거나 펄스 발생기의 배터리가 꺼지거나 심박 조율기의 제어 회로가 강한 자기장에 노출되어 손상을 입으면 오작동을 일으킬 수 있습니다.

목차

제1장 조사 방법 및 범위

제2장 정의 및 개요

제3장 주요 요약

제4장 시장 역학

  • 영향 요인
    • 성장 촉진 요인
      • 신제품 출시와 약사 승인 증가
      • 디바이스의 기술 진보 증가
    • 억제 요인
      • 기기와 관련된 빈번한 리콜
      • 기기 관련 합병증 및 위험
    • 기회
    • 영향 분석

제5장 산업 분석

  • Porter's Five Forces 분석
  • 공급망 분석
  • 가격 분석
  • 규제 분석
  • 러시아 우크라이나 전쟁의 영향 분석
  • DMI의 견해

제6장 COVID-19 분석

제7장 유형별

  • 부비동 서맥
  • 부비동 정지
  • 동부전 증후군
  • 빈맥성 서맥 증후군
  • 심장 블록

제8장 디바이스별

  • 페이스메이커
    • 단강 페이스메이커
    • 이강 페이스메이커
  • 제세동기

제9장 최종 사용자별

  • 병원
  • 전문 클리닉
  • 기타

제10장 지역별

  • 북미
    • 미국
    • 캐나다
    • 멕시코
  • 유럽
    • 독일
    • 영국
    • 프랑스
    • 이탈리아
    • 스페인
    • 기타 유럽
  • 남미
    • 브라질
    • 아르헨티나
    • 기타 남미
  • 아시아 태평양
    • 중국
    • 인도
    • 일본
    • 호주
    • 기타 아시아 태평양
  • 중동 및 아프리카

제11장 경쟁 구도

  • 경쟁 시나리오
  • 시황/점유율 분석
  • M&A 분석

제12장 기업 개요

  • Abbott
    • 기업 개요
    • 제품 포트폴리오와 설명
    • 재무 개요
    • 주요 동향
  • BIOTRONIK
  • NIHON KOHDEN CORPORATION
  • Lepu Medical Technology(Beijing) Co Ltd.
  • MEDICO SRL
  • OSCOR Inc
  • OSYPKA MEDICAL
  • MicroPort Scientific Corporation
  • Boston Scientific Corporation
  • Medtronic

제13장 부록

LYJ 23.09.25

Overview

Global Bradycardia Treatment Devices market reached US$ 8.9 billion in 2022 and is expected to reach US$ 13.07 billion by 2030, growing with a CAGR of 5.0% during the forecast period 2023-2030.

The global bradycardia treatment devices market has witnessed significant growth and transformations over the years, with various factors influencing its dynamics. Rising cardiovascular disorders such as slow heart rate, research and development and government investments in medical devices are among the key drivers impacting bradycardia treatment devices globally. After the challenging year of 2020, the bradycardia treatment devices industry showed decent resilience and adaptability.

Government investments in cardiovascular disorders, particularly in developing economies, will continue to drive utilization of pacemakers and boost the global bradycardia treatment devices market. The global bradycardia treatment devices industry is placing increasing emphasis on better management of bradycardia. The respective initiatives includes the use of other devices, such as defibrillators for treatment of bradycardia as sometimes they function as pacemakers.

The sinus bradycardia, accounts for over one third of the market share. Similarly, the North America dominates the bradycardia treatment devices market, capturing the largest market share of over 1/3rd. The region's rapid investments in healthcare and rising major players in the bradycardia treatment devices market globally, makes it the largest market share holder. United States has the largest pool of manufacturers as well as consumers.

Dynamics

Growing Novel Product Launches and Regulatory Approvals

Developed economies have been witnessing rapid growth in betterment of their healthcare sectors, driven by high income levels, investments and infrastructure development. Several countries have experienced substantial demand for bradycardia treatment devices, reflecting their expanding healthcare industries. Rising novel product launches along with regulatory approvals for the same will be a crucial factor driving the growth of the market.

On May 18, 2023, the Alizea and Celea implantable pacemakers, which are currently the longest-lasting pacemakers for their size on the market, as well as its associated products, SmartTouch XT tablet-based programmer, the Vega pacing leads, and SmartView Connect Bluetooth home monitor, have all received FDA approval, according to MicroPort CRM, a global pioneer in the field of Cardiac Rhythm Management with headquarters in France. This represents a huge victory for patient care and illustrates the firm's dedication to the American market. The AutoMRI mode, a ground-breaking algorithm created by MicroPort CRM, is a feature of the Alizea and Celea products.

It improves patient safety and quality of life while undergoing an MRI scan. To activate the MRI mode, patients just need to see their cardiologist once in the ten days before to their scan. Once the mode is set up, the pacemaker automatically shifts to the MRI mode while entering the MRI field and returns to its default settings after the exam, greatly enhancing the efficiency of both patients and medical personnel. These devices are approved for use in 1.5 or 3 Tesla MRI scanners when implanted with Vega pacing leads.

Rising Number of Technological Advancements in Devices

Rising technological advancements in the devices for treatment of bradycardia will drive the growth of the market in coming period of time. For instance, on May 20, 2023, the first dual-chamber leadless pacemaker in the world received late-breaking outcomes from the dual-chamber (DR) AVEIR i2i Investigational Device Exemption (IDE) research from Abbott, demonstrating that the pacemaker met its three predetermined primary endpoints for safety and performance. The information also implies that AVEIR DR might provide new advantages for those who have slower-than-normal heart rhythms.

With the first-of-its-kind i2i (implant-to-implant) technology, Abbott created the AVEIR DR leadless pacemaker-the DR standing for dual-chamber rate response-with the intention of enabling beat-to-beat communication and harmony between two leadless pacemakers, the cornerstone of dual-chamber leadless pacing therapy. By communicating with one another, the two devices are able to sense a missed or delayed heartbeat and subsequently pace the proper heart chamber, unlike other leadless pacemakers.

Frequent Recalls Associated with the Devices

Several recalls have been linked with these pacemakers owing to different reasons frequently in past few years. Foe instance, pacemakers from the Boston Scientific INGENIO family, also known as cardiovascular resynchronization therapy pacemakers (CRT-Ps), are used in patients with low heart rates and those who have moderate to severe heart failure, a disease in which the heart is unable to pump enough blood to meet the body's requirements.

On August 10, 2021, due to the possibility of entering safety mode, Boston Scientific has recalled CRT-Ps and pacemakers from the INGENIO family. If the device in question is broken, safety mode is meant to act as a backup. Due to the detection of muscle contractions, there is a danger of inadvertent pacing loss in safety mode. The device must be replaced if it enters safety mode since it cannot be reprogrammed.

The use of the impacted product may have severe negative health effects, such as the need for promptly device replacement, loss of heart rate control or pacing with serious or life-threatening injury (for instance, the requirement for temporary pacing in which a healthcare provider administers controlled electric pulses to regulate a heart), worsening heart failure, and death. There have been 65 documented incidences, three of which required temporary external pacing for the injured patients. There haven't been any reported fatalities.

Complications or Risks Related to the Device

A blood clot occurs in about 2% of pacemaker users. This typically occurs in the region of the arm on the side the pacemaker was implanted. The arm may enlarge as a result of this. However, it normally disappears within a few days. Rarely is it a major issue. A pacemaker infection affects 1% of those who have one. Within the initial year of using the device, this typically occurs. There is a chance that the surgery will unintentionally rupture the lung. This implies that air can seep into the chest from the lung. The term pneumothorax refers to this.

Only 1% of persons are affected. Usually, the leak is really little. One won't need therapy because it will get better on its own. The pacemaker has a tiny probability of failing, much like any electronic device. This is known as a pacemaker error. A pacemaker can malfunction if the lead is pushed out of place, the pulse generator's battery dies, or the pacemaker's control circuits are harmed by being subjected to powerful magnetic fields.

Segment Analysis

The global bradycardia treatment devices market is segmented based on type, devices, end user and region.

High Advantages and Advancements of Pacemaker Devices

A pacemaker keeps track of the beat of the heart. It sends electrical signals to the heart to enhance pace and bring about a normal rhythm if it notices an anomaly. Some pacemakers use leads, which are a number of wires surgically attached to the heart, to connect to the heart. A leadless pacemaker, which doesn't need wires, is implanted into the heart. Leadless pacemakers are implanted straight inside the heart and contain no wires. The physician makes a tiny incision through the groin to implant these pacemakers. He or she directs the heart with a catheter, a long, slender, hollow tube. The device, which is about the dimensions of a large vitamin, travels down the catheter. The right ventricular wall is where the leadless pacemaker is fixed.

A tiny device called a pacemaker containing leads is inserted beneath the skin of the chest. This pacemaker, which is about the size of a pair of half-dollars pushed together, is equipped with a small battery and computer that are connected via one or two leads, which are thin, flexible wires with insulation. The device's leads extend into the heart, wherein the tips include electrode sensors that track cardiac rhythm and transmit data to the pacemaker.

Geographical Penetration

North America Accounted for Largest Market Share in 2022, Owing to the Strong Presence of Major Players and Increasing Healthcare Infrastructure Investment

Due to the rising need for bradycardia treatment devices in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for bradycardia treatment devices.

Increasing expenditure on healthcare and rising research studies, advancement of technologies for different devices for bradycardia, and increase in pharmaceutical and medical devices business establishment across the region are also contributing to the growth of bradycardia treatment devices market share of this region.

The key healthcare organizations' and businesses' joint research initiatives are also expected to contribute to the rising demand, as will new product development, which constantly looks to improve present options. The market in this area is growing as people become more aware of various novel devices such as defibrillator, for treatment purposes. The aforementioned elements further attest to North America's hegemonic position in the world.

North America continues to be a key player in the global bradycardia treatment devices market, with United States leading the way. Government initiatives promoting infrastructure development and investment, and a focus on rising cardiovascular disorders have fueled the demand for bradycardia treatment devices in the region. United States have been proactive in executing several initiatives or researches, stimulating bradycardia treatment devices demand.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global bradycardia treatment devices market. As countries grappled with lockdowns, supply chain disruptions and reduced economic activity, the medical device sector, with a significant consumer of bradycardia treatment devices, was significantly impacted.

Several efforts all throughout the world were impacted by the pandemic's broad lockdowns and limitations that started in early 2020. Major pharmaceutical or medical device industries came to a standstill and shifted their attention towards the management of COVID-19, leading to a slump in demand for bradycardia treatment devices. As a result, many medical device plants either suspended or reduced production to align with the reduced demand.

The COVID-19 pandemic severely disrupted global supply chains, impacting the transportation of raw materials to the pharmaceuticals manufacturing plants. Movement limitations and border closures caused production and supply delays. Additionally, some nations experienced a lack of raw resources as a result of supply chain network interruptions.

With the outbreak of the pandemic, many pharmaceutical or medical device manufacturing units faced labor shortages as workers fell sick or were unable to travel to work due to lockdown restrictions. To curb the spread of the virus, pharmaceutical plants implemented stringent safety measures, reducing the number of workers allowed on-site at a time. However, these measures were vital to safeguard the health of the workforce and maintain essential operations during the pandemic.

Russia-Ukraine War Impact Analysis

The medical device businesses are starting to worry regarding their capacity to continue operating, much like other parts of the world. Russia's invasion of Ukraine has an effect on millions of people not only in this nation in Eastern Europe but also all around the world. Device developers will thus experience delays in the development process, a loss of business consistency, and the possibility of non-compliance for devices/drugs already on the market.

For many years, clinical trials in several therapeutic fields have benefited significantly from the participation of Ukraine, Russia, and other CIS nations. Clinical trial durations can frequently be accelerated by incorporating more patients into studies when there is availability to skilled investigators, high-quality patient populations, and big patient populations. Trials that are delayed in Russia and Ukraine as well as relocation to other regions of Europe for fresh trials are currently viable choices. These factors will impact the global bradycardia treatment devices market.

By Type

  • Sinus Bradycardia
  • Sinus Pause
  • Sick Sinus Syndrome
  • Tachy-brady Syndrome
  • Heart Block

By Devices

  • Pacemakers
    • Single Chamber Pacemaker
    • Dual Chamber Pacemaker
  • Defibrillator

By End User

  • Hospitals
  • Specialty Clinics
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • On July 5, 2023, the AVEIR dual chamber leadless pacemaker system, the first dual chamber leadless pacing system in the world that serves patients with aberrant or sluggish heart rhythms, has received FDA approval, according to a statement from Abbott. The approval dramatically expands the availability of leadless pacing for hundreds of thousands of people across the United States because more than 80% of persons who require a pacemaker require pacing both in the right atrium and the right ventricle.
  • On May 1, 2023, the FDA has given the green light to the next generation of the company's industry-leading miniaturized, lead-free pacemakers, the Micra AV2 and Micra VR2, according to Medtronic plc, an international innovator in healthcare technology. The Micra AV2 and Micra VR2, the smallest pacemakers in the world, provide more battery life and easier programming than earlier Micra models while still offering the many benefits of leadless pacing, including fewer issues than conventional pacemakers.

Competitive Landscape

The major global players in the market include: Abbott, BIOTRONIK, NIHON KOHDEN CORPORATION, Lepu Medical Technology (Beijing) Co Ltd., MEDICO S.R.L., OSCOR Inc, OSYPKA MEDICAL, MicroPort Scientific Corporation, Boston Scientific Corporation and Medtronic.

Why Purchase the Report?

  • To visualize the global bradycardia treatment devices market segmentation based on type, devices, end user and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of bradycardia treatment devices market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global bradycardia treatment devices market report would provide approximately 61 tables, 58 figures and 186 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Devices
  • 3.3. Snippet by End User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing Novel Product Launches and Regulatory Approvals
      • 4.1.1.2. Rising Number of Technological Advancements in Devices
    • 4.1.2. Restraints
      • 4.1.2.1. Frequent Recalls Associated with the Devices
      • 4.1.2.2. Complications or Risks Related to the Device
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Russia-Ukraine War Impact Analysis
  • 5.6. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Sinus Bradycardia*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Sinus Pause
  • 7.4. Sick Sinus Syndrome
  • 7.5. Tachy-brady Syndrome
  • 7.6. Heart Block

8. By Devices

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Devices
    • 8.1.2. Market Attractiveness Index, By Devices
  • 8.2. Pacemakers*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 8.2.3. Single Chamber Pacemaker
    • 8.2.4. Dual Chamber Pacemaker
  • 8.3. Defibrillator

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Specialty Clinics
  • 9.4. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Devices
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Devices
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Devices
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Devices
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Devices
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Abbott*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. BIOTRONIK
  • 12.3. NIHON KOHDEN CORPORATION
  • 12.4. Lepu Medical Technology (Beijing)Co Ltd.
  • 12.5. MEDICO S.R.L.
  • 12.6. OSCOR Inc
  • 12.7. OSYPKA MEDICAL
  • 12.8. MicroPort Scientific Corporation
  • 12.9. Boston Scientific Corporation
  • 12.10. Medtronic

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제